These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 9145977)
1. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Bazinet M; Zheng W; Bégin LR; Aprikian AG; Karakiewicz PI; Elhilali MM Urology; 1997 May; 49(5):721-5. PubMed ID: 9145977 [TBL] [Abstract][Full Text] [Related]
2. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate]. Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044 [TBL] [Abstract][Full Text] [Related]
4. [Histological investigation of prostate cancer treated with hormonal agents]. Azumi M; Saga Y; Hashimoto H; Kakizaki H Hinyokika Kiyo; 2006 Oct; 52(10):781-4. PubMed ID: 17131867 [TBL] [Abstract][Full Text] [Related]
5. Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma. Unger PD; Wang Q; Gordon RE; Stock R; Stone N Arch Pathol Lab Med; 1997 Dec; 121(12):1265-8. PubMed ID: 9431316 [TBL] [Abstract][Full Text] [Related]
7. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. Wieder JA; Soloway MS J Urol; 1998 Aug; 160(2):299-315. PubMed ID: 9679867 [TBL] [Abstract][Full Text] [Related]
8. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. Fair WR; Betancourt JE Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380 [TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results. Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y; Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545 [TBL] [Abstract][Full Text] [Related]
10. Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma. Têtu B Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):271-83. PubMed ID: 18471785 [TBL] [Abstract][Full Text] [Related]
11. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors]. Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198 [TBL] [Abstract][Full Text] [Related]
12. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167 [TBL] [Abstract][Full Text] [Related]
13. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446 [TBL] [Abstract][Full Text] [Related]
14. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery. Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876 [TBL] [Abstract][Full Text] [Related]
15. Lipofuscin pigment can be used as a prognostic marker in prostatic adenocarcinoma. Mahmoodi M; Zhang S; Salim S; Hou JS; Garcia FU Ann Diagn Pathol; 2006 Oct; 10(5):257-62. PubMed ID: 16979516 [TBL] [Abstract][Full Text] [Related]
16. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy. Chuang AY; Nielsen ME; Hernandez DJ; Walsh PC; Epstein JI J Urol; 2007 Oct; 178(4 Pt 1):1306-10. PubMed ID: 17698141 [TBL] [Abstract][Full Text] [Related]
17. [Anatomical and clinical effects of neoadjuvant hormonal treatment before radical prostatectomy]. Tostain J; Versini P; Legon C; Li G; Ludot T; Castro R; Armand C; Boucheron S Prog Urol; 1997 Sep; 7(4):570-8. PubMed ID: 9410314 [TBL] [Abstract][Full Text] [Related]
18. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Blute ML; Bostwick DG; Bergstralh EJ; Slezak JM; Martin SK; Amling CL; Zincke H Urology; 1997 Nov; 50(5):733-9. PubMed ID: 9372884 [TBL] [Abstract][Full Text] [Related]